ZA922834B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA922834B
ZA922834B ZA922834A ZA922834A ZA922834B ZA 922834 B ZA922834 B ZA 922834B ZA 922834 A ZA922834 A ZA 922834A ZA 922834 A ZA922834 A ZA 922834A ZA 922834 B ZA922834 B ZA 922834B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA922834A
Other languages
English (en)
Inventor
Peter Gassmann
Heinz Sucker
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA922834(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of ZA922834B publication Critical patent/ZA922834B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
ZA922834A 1991-04-19 1992-04-16 Pharmaceutical compositions ZA922834B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24
PCT/EP1992/000862 WO1992018105A1 (en) 1991-04-19 1992-04-16 Improvements in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA922834B true ZA922834B (en) 1993-10-18

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922834A ZA922834B (en) 1991-04-19 1992-04-16 Pharmaceutical compositions

Country Status (16)

Country Link
EP (1) EP0580690B2 (xx)
JP (1) JP3695754B2 (xx)
AT (1) AT410896B (xx)
AU (1) AU1577992A (xx)
CA (1) CA2108018C (xx)
DE (1) DE4291156T1 (xx)
ES (1) ES2069995T5 (xx)
FR (1) FR2675382B1 (xx)
GB (1) GB2269536B (xx)
IE (1) IE921230A1 (xx)
IL (1) IL101635A0 (xx)
IT (1) IT1254323B (xx)
MX (1) MX9201782A (xx)
NO (1) NO933695D0 (xx)
WO (1) WO1992018105A1 (xx)
ZA (1) ZA922834B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH09505308A (ja) * 1993-11-19 1997-05-27 アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー 生物学的活性剤を含有する生分解性微粒子の製造
DE69633222T2 (de) * 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
IL162023A0 (en) 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1287769C (zh) 1998-11-20 2006-12-06 斯凯伊药品加拿大公司 可分散的磷脂稳定的微粒
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
CA2669392C (en) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP3586845A1 (en) 2016-08-11 2020-01-01 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ, インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (xx) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
BE1003009A5 (fr) 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.

Also Published As

Publication number Publication date
IE921230A1 (en) 1992-10-21
CA2108018C (en) 2003-04-15
CA2108018A1 (en) 1992-10-20
ES2069995T3 (es) 1995-05-16
EP0580690B2 (en) 2000-09-13
DE4291156T1 (de) 1994-10-20
IL101635A0 (en) 1992-12-30
AT410896B (de) 2003-08-25
IT1254323B (it) 1995-09-14
WO1992018105A1 (en) 1992-10-29
AU1577992A (en) 1992-11-17
ATA901092A (de) 2003-01-15
NO933695D0 (no) 1993-10-14
JPH06506926A (ja) 1994-08-04
EP0580690B1 (en) 1995-03-15
MX9201782A (es) 1992-10-01
ES2069995T5 (es) 2000-11-16
GB2269536A (en) 1994-02-16
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
GB2269536B (en) 1995-05-10
EP0580690A1 (en) 1994-02-02
FR2675382B1 (fr) 1995-05-12
ITRM920281A1 (it) 1993-10-16
FR2675382A1 (fr) 1992-10-23
JP3695754B2 (ja) 2005-09-14

Similar Documents

Publication Publication Date Title
HU9303143D0 (en) Pharmaceutical compositions
GB9213393D0 (en) Pharmaceutical composition
GB9210579D0 (en) Pharmaceutical composition
GB9210974D0 (en) Pharmaceutical composition
ZA922834B (en) Pharmaceutical compositions
GB9203084D0 (en) Pharmaceutical composition
GB9108080D0 (en) Pharmaceutical composition
GB9200253D0 (en) Pharmaceutical compositions
ZA925171B (en) Pharmaceutical compositions
GB9120672D0 (en) Pharmaceutical compositions
GB9121631D0 (en) Pharmaceutical compositions
GB2252497B (en) Pharmaceutical composition
GB9200414D0 (en) Pharmaceutical compositions
GB9111477D0 (en) Pharmaceutical composition
GB9119048D0 (en) Pharmaceutical compositions
GB9113621D0 (en) Pharmaceutical compositions
GB9123423D0 (en) Pharmaceutical compositions
GB9121989D0 (en) Pharmaceutical compositions
GB9121291D0 (en) Pharmaceutical compositions
GB9100464D0 (en) Pharmaceutical compositions
GB9107278D0 (en) Pharmaceutical compositions
GB9118481D0 (en) Pharmaceutical compositions
GB9108643D0 (en) Pharmaceutical compositions
GB9118128D0 (en) Pharmaceutical compositions
GB9113805D0 (en) Pharmaceutical compositions